Compare DSS & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DSS | CMND |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 1.4M |
| IPO Year | 2020 | 2021 |
| Metric | DSS | CMND |
|---|---|---|
| Price | $0.83 | $1.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.6K | ★ 118.7K |
| Earning Date | 05-14-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.45 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,085,000.00 | N/A |
| Revenue This Year | $14.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.72 | $0.07 |
| 52 Week High | $1.90 | $3.25 |
| Indicator | DSS | CMND |
|---|---|---|
| Relative Strength Index (RSI) | 47.00 | 53.25 |
| Support Level | $0.85 | $0.99 |
| Resistance Level | $0.97 | $1.08 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.00 | 0.07 |
| Stochastic Oscillator | 42.86 | 90.99 |
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia. Product packaging manufactures, and sells sophisticated custom folding cartons, mailers, photo sleeves and complex three-dimensional direct mail solutions. Biotechnology division targets unmet, urgent medical needs and expands the borders of medical and pharmaceutical science. Commercial Lending through represents its banking and financing business line. Alternative Trading develops and/or acquires assets and investments in the securities trading and/or fund management arena.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.